Hello, Sign in
My Account
My Account
New customer? Start here
| Catalog # | Availability | Size | Quantity | Unit Price | Save For Later Wish List | |
|---|---|---|---|---|---|---|
| GRF0379-2 | 7 days | 2 µg | $120.00 |
Select product before adding to cart
|
||
| GRF0379-10 | 7 days | 10 µg | $290.00 | |||
| GRF0379-1 | 7 days | 1 mg | $7,488.00 |
Product Overview | |
| Name | sRANKL Human |
|---|---|
| Description | |
| RANK Ligand Soluble Human Recombinant | |
| Accession (Primary) | O14788 |
| Synonyms | |
| Soluble Receptor Activator of NFkB Ligand, TNFSF11, TRANCE, TNF-related activation-induced cytokine, OPGL, ODF, Osteoclast differentiation factor, Tumor necrosis factor ligand superfamily member 11, Receptor activator of nuclear factor kappa B ligand, RANKL, Osteoprotegerin ligand, CD254 antigen, sRANKL, sOdf, hRANKL2. | |
| Introduction | |
| RANKL binds to tnfrsf11b/opg and to tnfrsf11a/rank. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive t-cell proliferation. May be an important regulator of interactions between t-cells and dendritic cells and may play a role in the regulation of the t-cell-dependent immune response. sRANKL may also play an important role in enhanced bone-resorption in humoral hypercalcemia of malignancy. By injecting soluble RANKL, novel osteopenia model mice were established in only 50 hours. Degree of bone loss can be controlled by changing doses of sRANKL. RANKL can be used in establishing osteopenia model for in vivo screening of drugs for osteoporosis, determination of effect and mechanism, evaluation of bone anabolic drugs. | |
| Source | |
| Escherichia Coli. | |
| Physical Appearance | |
| Sterile Filtered colorelss clear solution. | |
| Formulation | |
| The soluble RANKL protein solution contains 1mM EDTA and PBS pH-7.4. | |
| Stability | |
| Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. Please avoid freeze thaw cycles. | |
| Purity | |
| Greater than 95.0% as determined by SDS-PAGE. | |
| Precautions | |
| sRANKL Human is for research use only and not for use in diagnostic or therapeutic procedures. | |
Target Information: ( O14788 ) | |
References |
1. Title :Cathepsin K Expression and Activity in Canine Osteosarcoma. Publication : Article first published online: 15 DEC 2011 DOI:10.1111/j.1939-1676.2011.00834.x Copyright © 2011 by the American College of Veterinary Internal Medicine. Link : sRANKL prospec publication 2.Title : Grape Seed Procyanidin Reversal of P-glycoprotein Associated Multi-Drug Resistance via Down-regulation of NF-?B and MAPK/ERK Mediated YB-1 Activity in A2780/T Cells Publication : DOI: 10.1371/journal.pone.0071071, August 15, 2013 Link : RANK Ligand Soluble prospec publication |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from ADMEbio to advance their research.
Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
Thank you,
ADMEbio Team
ADMEbio welcomes feedback from our customers.
Thank you,
ADMEbio Team
